Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey

BMC Neurology
Hyun Kyoo Yoo1, A Porteous2, Alvin Wei Tian Ng3, Keval Haria2, A Griffiths4, Andrew Lloyd5, Xiaoqin Yang6, Gbenga Kazeem7, Volkan Barut7
1Alexion, AstraZeneca Rare Disease, Cambridge, UK
2Costello Medical, London, UK
3Costello Medical, Singapore, Singapore
4Costello Medical, Cambridge, UK
5Acaster Lloyd Consulting, London, UK
6Merck & Co., Inc., Rahway, USA
7AstraZeneca, Cambridge, UK

Tóm tắt

Abstract Background Plexiform neurofibromas (PN) are complex, benign nerve-sheath tumours that occur in 30–50% of patients with neurofibromatosis type 1 (NF1), a rare, genetic disorder. PN are associated with substantial, heterogeneous morbidities that impact health-related quality of life (HRQoL), including affecting motor function and causing pain, though HRQoL and work productivity data are scarce. This UK cross-sectional study explored HRQoL and work productivity in adult patients with NF1 PN and caregivers of paediatric patients. Methods Adult patients and caregivers of paediatric patients self-enrolled in an online survey (March–April 2021). Outcomes included EQ-5D-5L, PROMIS® GH and INF1-QOL (adult patients only), and EQ-5D-5L, CarerQol and WPAI (caregivers only). Utilities were estimated from EQ-5D-5L responses using the UK crosswalk value set. Linear regression models explored univariable associations between adult patient characteristics and HRQoL. Results Mean (± standard deviation) EQ-5D utility in adult patients with NF1 PN was 0.65 (± 0.29; n = 35; age-/sex-matched norm: 0.89 [± 0.04]). Moderate–extreme pain/discomfort and anxiety/depression were reported by 14/35 (40.0%) and 18/35 (51.4%) patients, respectively. Mean PROMIS® GH physical and mental health scores were 43.6 (± 9.19) and 41.7 (± 11.5; n = 35; matched norm: 50.0 [± 10.0]). Mean INF1-QOL score was 11.03 (± 6.02; n = 33). Chronic itching, at least one symptom, at least one comorbidity, PN location at extremities (arms/legs) and pain were associated with worse HRQoL scores. Mean caregiver EQ-5D utility was 0.72 (± 0.24; n = 8; age-/sex-matched norm: 0.88 [± 0.03]). Moderate pain/discomfort and moderate–severe anxiety/depression were reported by 4/8 (50.0%) and 2/8 (25.0%) caregivers, respectively. Mean CarerQol score was 69.3 (± 13.9; n = 8). Mean WPAI regular activity productivity loss was 36.3% (± 31.6%; n = 8). Conclusions NF1 PN worsens adult patient and caregiver HRQoL compared to the general population, notably affecting pain and discomfort, anxiety and depression and caregiver productivity.

Từ khóa


Tài liệu tham khảo

Poyhonen M, Kytölä S, Leisti J. Epidemiology of neurofibromatosis type 1 (NF1) in northern Finland. J Med Genet. 2000;37(8):632–6.

Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152a(2):327–32.

Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81–8.

Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012;7:75.

Le LQ, Liu C, Shipman T, Chen Z, Suter U, Parada LF. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Can Res. 2011;71(13):4686–95.

Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430–42.

Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol. 2018;20(12):1643–51.

Koerling A-L. No friends 1. Orphanet J Rare Dis. 2020;15(1):50.

Lai JS, Jensen SE, Patel ZS, Listernick R, Charrow J. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan. Am J Med Genet A. 2017;173(1):79–87.

Wolters PL, Burns KM, Martin S, Baldwin A, Dombi E, Toledo-Tamula MA, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167(9):2103–13.

Lai J-S, Jensen SE, Charrow J, Listernick R. Patient reported outcomes measurement information system and quality of life in neurological disorders measurement system to evaluate quality of life for children and adolescents with neurofibromatosis type 1 associated plexiform neurofibroma. J Pediatr. 2019;206:190–6.

Ferner RE, Thomas M, Mercer G, Williams V, Leschziner GD, Afridi SK, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15(1):1–6.

Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neorooncol Adv. 2020;2(Suppl 1):i141–9.

Vranceanu AM, Merker VL, Park ER, Plotkin SR. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015;122(2):219–28.

Lawrence C, Yoo, H.K. Yang X., Kazeem G., Barut V., Lloyd A.J., Lo S.H. Patient and caregiver burden in neurofibromatosis type 1 (NF1) with plexiform neurofibroma (PN). Virtual Neurofibromatosis (NF) Conference. 2021:112.

Yang X, Yoo HK, Amin S, Cheng WY, Sundaresan S, Zhang L, et al. Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: a cross-sectional study. Neurol Ther. 2022;11(3):1221–33.

Li L, Liu C, Cai X, Yu H, Zeng X, Sui M, et al. Validity and reliability of the EQ-5D-5 L in family caregivers of leukemia patients. BMC Cancer. 2019;19(1):522.

Orgeta V, Edwards RT, Hounsome B, Orrell M, Woods B. The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers. Qual Life Res. 2015;24(2):315–24.

Hoefman RJ, van Exel J, Brouwer WB. Measuring the impact of caregiving on informal carers: a construct validation study of the CarerQol instrument. Health Qual Life Outcomes. 2013;11(1):173.

Hoefman RJ, van Exel J, Brouwer WB. Measuring care-related quality of life of caregivers for use in economic evaluations: CarerQol tariffs for Australia, Germany, Sweden, UK, and US. Pharmacoeconomics. 2017;35(4):469–78.

McLoughlin C, Goranitis I, Al-Janabi H. Validity and responsiveness of preference-based quality-of-life measures in informal carers: a comparison of 5 measures across 4 conditions. Value Health. 2020;23(6):782–90.

Voormolen DC, van Exel J, Brouwer W, Sköldunger A, Gonçalves-Pereira M, Irving K, et al. A validation study of the CarerQol instrument in informal caregivers of people with dementia from eight European countries. Qual Life Res. 2021;30(2):577–88.

Giovannetti ER, Wolff JL, Frick KD, Boult C. Construct validity of the work productivity and activity impairment questionnaire across informal caregivers of chronically ill older patients. Value Health. 2009;12(6):1011–7.

Dean BB, Calimlim BC, Sacco P, Aguilar D, Maykut R, Tinkelman D. Uncontrolled asthma: assessing quality of life and productivity of children and their caregivers using a cross-sectional Internet-based survey. Health Qual Life Outcomes. 2010;8(1):96.

van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.

EQ-5D-5L | Valuation | Crosswalk Index Value Calculator. https://euroqol.org/support/analysis-tools/index-value-set-calculators/. Accessed 4 June 2021.

National Institute for Health and Care Excellence (NICE). Position statement on use of EQ-5D-5L value set for England. 2017 (updated October 2019). https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l. Accessed 3 August 2021.

Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.

CarerQol utility tariffs - 6 countries. https://www.imta.nl/assets/uploads/2017/02/Tariffs-CarerQol_6-countries.pdf linked via https://www.imta.nl/questionnaires/carerqol/. Accessed 22 Oct 2021.

den Hollander D, Van der Graaf WTA, Fiore M, Kasper B, Singer S, Desar IME, et al. Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on tumour location. ESMO open. 2020;5(5):e000914-e.

Baji P, Brouwer WBF, van Exel J, Golicki D, Prevolnik Rupel V, Zrubka Z, et al. Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. Qual Life Res. 2021;30(2):629–41.

Mercer UK. Unhealthy employees now cost British firms six working weeks a year in lost productivity. 2021. https://www.uk.mercer.com/newsroom/Unhealthy-employees-now-cost-British-firms-six-working-weeks-a-year-in-lost-productivity.html. Accessed 3 August 2021.

Thông tin
Thông tin xuất bản

BMC Neurology

Thông tin tác giả